Ionis Pharmaceuticals, Inc.
Antisense Compounds and Uses Thereof
Last updated:
Abstract:
The present invention provides compounds comprising oligonucleotides complementary to a CLN3 transcript. Certain such compounds are useful for hybridizing to a CLN3 transcript, including but not limited to a CLN3 transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the CLN3 transcript. In certain embodiments, such compounds are used to treat one or more symptoms associated with Batten Disease.
Status:
Application
Type:
Utility
Filling date:
9 Aug 2019
Issue date:
9 Jul 2020